IL Class Action Claims Walgreens Failed To Warn Consumers of Valsartan Dangers

 Illinois class action claims that Walgreens failed to warn consumers that one of the high blood pressure medications available from the pharmacy, Valsartan, was a toxic drug containing a suspected carcinogen.

The lawsuit was filed in Cook County Circuit Court on Friday. The lawsuit claims that Walgreens Boots Alliance Inc. materially misrepresented the safety of Valsartan, which had been recalled by the FDA due to the presence of probable carcinogen N-nitrosodimethylamine, or NDMA, and N-nitrosodiethylamine, or NDEA, a suspected human and known animal carcinogen.

Plaintiffs claim that Walgreens was aware that the product was toxic, but failed to warn consumers, putting them at risk.

Harry Shanov, plaintiff, said that if he, himself, or other members of the class action knew of the alleged health risks associated with Valsartan, they would have not purchased the product.

According to the complaint, plaintiff consumers believed that they were purchasing Valsartan “and only Valsartan, as opposed to Valsartan that contained elevated and unsafe levels of NDMA and NDEA.”

Shanov says that his prescription was also misleading. Based on the label of his prescription, he believed that Valsartan did not pose any “undisclosed increased risk” of health risks.


Third Blood Pressure Medication, Losartan, Recalled

The FDA announced a third blood pressure medication recall because of possible contamination that can cause cancer. Sandoz Inc. is “voluntarily recalling losartan potassium hydrochlorothiazide tablets because the pills could contain an impurity N-nitrosodiethylamine (NDEA),” which is a “probable human carcinogen, according to the International Agency for Research on Cancer.” Losartan affected by the recall is 100 milligram/25-milligram tablets with the lot number JB8912.

Teva Confirms Voluntary Recall of Valsartan

Teva Pharmaceuticals USA confirmed a voluntary recall to all consumers/user level of 29 lots of single & 51 lots of combination Actavis valsartan medicines. This includes any products whose active ingredient is valsartan or valsartan and hydrochlorothiazide.

This voluntary recall was issued after trace amounts of N-nitrosodimethylamine (NDMA) were discovered in valsartan products. It should be noted that this recall also follows a mandated recall by the FDA – the agency issued a full recall of all blood pressure and heart failure medication with the active ingredient valsartan or valsartan and hydrochlorothiazide.



One of our associates will follow up with you shortly